This inventor holds 1 USPTO granted patent. Top assignee: Elan Pharmaceuticals, Inc.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Chris Vandevert: Innovator in Inflammatory Disease Treatment
Introduction
Chris Vandevert is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of medicine, particularly in the treatment of inflammatory diseases. His innovative work has led to the development of a patent that addresses critical health issues affecting many individuals.
Latest Patents
Chris Vandevert holds a patent for "Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids." This patent discloses conjugates that bind VLA-4, which play a crucial role in inhibiting leukocyte adhesion. These conjugates are particularly useful in treating various inflammatory diseases in mammalian patients, including asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. Additionally, they can be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. He has 1 patent to his name.
Career Highlights
Chris Vandevert is currently associated with Elan Pharmaceuticals, Inc., where he continues to work on innovative solutions for health challenges. His expertise and dedication to research have positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Some of his notable coworkers include Andrei William Konradi and Michael A Pleiss. Their collaborative efforts contribute to the advancement of medical research and the development of effective treatments.
Conclusion
Chris Vandevert's contributions to the field of medicine through his innovative patents highlight his commitment to improving health outcomes for patients with inflammatory diseases. His work continues to inspire advancements in medical research and treatment options.